
    
      Anti-angiogenesis seems have positive effects on tumor immune microenvironment. the
      combination of PD-1/PD-L1 inhibitors and TKIs exhibited favorable efficacy on
      gastrointestinal malignancies. Here the investigators want to examine the efficacy and
      survival benefit from the combination therapy to PD-1 acquired resistance patients, which
      turns out to be critical issues in recent years.
    
  